KR100556865B1 - Fe(ⅲ), 폴리히드록실레이트 및 오브알부민으로 구성된 복합체 - Google Patents
Fe(ⅲ), 폴리히드록실레이트 및 오브알부민으로 구성된 복합체 Download PDFInfo
- Publication number
- KR100556865B1 KR100556865B1 KR1019980007123A KR19980007123A KR100556865B1 KR 100556865 B1 KR100556865 B1 KR 100556865B1 KR 1019980007123 A KR1019980007123 A KR 1019980007123A KR 19980007123 A KR19980007123 A KR 19980007123A KR 100556865 B1 KR100556865 B1 KR 100556865B1
- Authority
- KR
- South Korea
- Prior art keywords
- complex
- solution
- iii
- polyhydroxylate
- iron
- Prior art date
Links
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 108010058846 Ovalbumin Proteins 0.000 title claims description 23
- 229940092253 ovalbumin Drugs 0.000 title claims description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 69
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 57
- 229910052742 iron Inorganic materials 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 239000002244 precipitate Substances 0.000 claims description 19
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 17
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 17
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 108010088751 Albumins Proteins 0.000 claims description 13
- 102000009027 Albumins Human genes 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000005194 fractionation Methods 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 125000001477 organic nitrogen group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000021434 dietary agent Nutrition 0.000 claims 1
- 230000005672 electromagnetic field Effects 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 238000001226 reprecipitation Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000002211 ultraviolet spectrum Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 description 8
- 108050000784 Ferritin Proteins 0.000 description 8
- 238000008416 Ferritin Methods 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001362 electron spin resonance spectrum Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 150000002505 iron Chemical class 0.000 description 3
- 159000000014 iron salts Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 235000014413 iron hydroxide Nutrition 0.000 description 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000247617 Teramnus labialis var. labialis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940010514 ammonium ferrous sulfate Drugs 0.000 description 1
- XGGLLRJQCZROSE-UHFFFAOYSA-K ammonium iron(iii) sulfate Chemical compound [NH4+].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XGGLLRJQCZROSE-UHFFFAOYSA-K 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000005414 paramagnetic center Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
- Fe(III), 폴리히드록실레이트 화합물 및 오브알부민으로 이루어진 복합체를 제조하는 방법에 있어서, 상기 폴리히드록실레이트 화합물이 만니톨, 소르비톨 및 프럭토오스로 이루어진 군으로부터 선택되며 상기 방법이,A) 알부민 수용액에서 출발하여 오브알부민 수용액을 제조하는 단계로서, 알부민 수용액을 포화도 0.32의 황산암모늄으로 처리하여 침전물을 형성한 다음, 그 침전물은 제거하고 생기는 용액을 다시 포화도 0.52의 황산 암모늄으로 처리하여 오브알부민 침전물을 얻은 후, 이 오브알부민 침전물을 물에 재용해시킨후 정제하고 약 5%로 농축한후 여기에 NaOH를 가해 pH를 9로 만드는 것을 특징으로 하는 단계;B) Fe(Ⅲ)과 폴리히드록실레이트 화합물로 이루어진 복합체 용액을 제조하는 단계로서, 폴리히드록실레이트 화합물에 모어염(Mohr's salt)을 가하고 이어서 H2O2를 가해 Fe(Ⅱ)을 Fe(Ⅲ)으로 산화시킨 후, pH 10.5가 될 때까지 NaOH를 가하는 것을 특징으로 하는 단계; 및C) (A)와 (B)에 기재된 방법으로 얻은 용액을 혼합하여 Fe(Ⅲ)-폴리히드록실레이트-오브알부민 복합체를 형성하고, pH가 5.0 내지 5.5가 될 때까지 아세트산을 가해 복합체를 침전시킨 후 정제하는 단계;를 포함하는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 포화도 0.32의 황산암모늄으로 처리한 상기 알부민 용액은 농도가 2-5%이고 온도가 5-10℃이고 pH가 3-5인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 오브알부민 용액의 정제는 여과후 분자 분류 칼럼 분리 20,000 한외여과에 의해 수행되는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 폴리히드록실레이트 화합물이 첨가되는 상기 모어염 수용액은 농도가 3-5%이고 온도가 10-15℃인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 폴리히드록실레이트 화합물은 모어염 2.5mol당 0.5mol의 양으로 모어염 용액에 첨가되는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 과산화수소의 첨가량은 모어염 2.5mol당 과산화수소 0.25mol인 것을 특징으로 하는 방법.
- 제 1항에 있어서, (A)단계 및 (B)단계에서 얻어지는 용액의 혼합은, 모어염 2.5mol과 폴리히드록실레이트 화합물 0.5mol로부터 얻은 복합체와 0.01mol의 알부민을 혼합하는 것임을 특징으로 하는 방법.
- 제 1항에 있어서, 상기 침전 화합물의 정제는, 이 침전을 글리세롤 10중량%를 함유하는 pH 8의 수용액에 녹인 후 포화도 0.28의 황산암모늄을 가해 재침전시킨 다음 여과 및 세척하고, 마지막으로 글리세롤 10중량%를 함유하는 pH 8의 수용액에 다시 녹인후 분자 분류 칼럼 20,000으로 한외여과하여 정제함으로써 이루어지는 것을 특징으로 하는 방법.
- Fe(Ⅲ), 폴리히드록실레이트 화합물 및 오브알부민으로 구성되는 Fe(Ⅲ) 유기 복합체.
- 제 9항에 있어서, 상기 폴리히드록실레이트 화합물은 만니톨, 소르비톨 및 프럭토오스로 구성된 군에서 선택되는 것임을 특징으로 하는 복합체.
- 제 9항에 있어서, 상기 복합체는 철의 총량이 135-185mg/g 이고 이중 유기 철의 함량이 97%이며 유기 질소의 함량이 80-95mg/g인 것을 특징으로 하는 복합체.
- 제 9항에 있어서, 가시광선-UV 스펙트럼에 있어서 가시광선 파장영역에는 최대치가 없고 270nm에는 밴드가 존재하며, 9GHZ의 주파수와 123°K의 온도에서의 전자상자기공명(EPR) 스펙트럼에 있어서 3000가우스 근처에 시그날이 존재하는 것을 특징으로 하는 복합체.
- 활성성분으로서 제 9항에 따른 Fe(Ⅲ) 유기 복합체를 포함하는 철결핍성 빈혈증 치료용 약제학적 조성물.
- 제 9항에 따른 Fe(Ⅲ) 유기 복합체를 유효량 경구투여하는 단계를 포함하는, 인간을 제외한 동물의 철결핍성 빈혈증 치료 방법.
- 제 9항에 따른 Fe(Ⅲ) 유기 복합체를 포함하는 식이요법제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT97MI001012A IT1291289B1 (it) | 1997-04-30 | 1997-04-30 | Complessi costituiti da fe(iii) un composto poliidrossilato e ovalbumina |
ITMI97A001012 | 1997-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19980079897A KR19980079897A (ko) | 1998-11-25 |
KR100556865B1 true KR100556865B1 (ko) | 2006-06-08 |
Family
ID=11377044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980007123A KR100556865B1 (ko) | 1997-04-30 | 1998-03-04 | Fe(ⅲ), 폴리히드록실레이트 및 오브알부민으로 구성된 복합체 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0875249B1 (ko) |
KR (1) | KR100556865B1 (ko) |
DE (1) | DE69811977D1 (ko) |
IT (1) | IT1291289B1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19858188A1 (de) * | 1998-12-17 | 2000-07-06 | Centeon Pharma Gmbh | Verfahren zum Auflösen von Albuminflocken in einer Flüssigkeit sowie Einrichtung zur Durchführung des Verfahrens |
DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
ES2258391B1 (es) * | 2004-11-03 | 2007-12-01 | Tedec-Meiji Farma, S.A. | Aducto de ovoalbumina soluble con complejos polialcoholicos de hierro trivalente y metodo para su obtencion. |
SI2593081T1 (sl) | 2010-07-15 | 2014-07-31 | Tedec-Meiji Farma, S.A. | Sestavek tablet iz ferimanitol-ovalbumina |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537634A2 (en) * | 1991-10-16 | 1993-04-21 | Mediolanum Farmaceutici S.P.A. | Iron complexes containing conalbumin and its derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1150213B (it) * | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
JPH021500A (ja) * | 1988-02-26 | 1990-01-05 | Q P Corp | コンアルブミン及びその金属複合体の製造方法 |
IT1237783B (it) * | 1989-11-16 | 1993-06-17 | Italfarmaco Spa | Derivati di ferro-albumina biodisponibile, loro procedimento di preparazione e relative composizioni farmaceutiche. |
JP2884045B2 (ja) * | 1994-03-18 | 1999-04-19 | 雪印乳業株式会社 | 鉄−ラクトフェリン複合体及びその製造法 |
-
1997
- 1997-04-30 IT IT97MI001012A patent/IT1291289B1/it active IP Right Grant
-
1998
- 1998-03-04 KR KR1019980007123A patent/KR100556865B1/ko not_active IP Right Cessation
- 1998-04-28 EP EP98107887A patent/EP0875249B1/en not_active Expired - Lifetime
- 1998-04-28 DE DE69811977T patent/DE69811977D1/de not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537634A2 (en) * | 1991-10-16 | 1993-04-21 | Mediolanum Farmaceutici S.P.A. | Iron complexes containing conalbumin and its derivatives |
Also Published As
Publication number | Publication date |
---|---|
ITMI971012A1 (it) | 1998-10-30 |
EP0875249A1 (en) | 1998-11-04 |
DE69811977D1 (de) | 2003-04-17 |
IT1291289B1 (it) | 1999-01-07 |
KR19980079897A (ko) | 1998-11-25 |
ITMI971012A0 (ko) | 1997-04-30 |
EP0875249B1 (en) | 2003-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4493829A (en) | Bio-available succinylated protein-iron derivatives which do not cause gastric lesions, method of preparation and related pharmaceutical compounds | |
JPS5942683B2 (ja) | 必須金属イオン複合体 | |
KR20080086446A (ko) | 철(ⅲ)-숙시닐카세인의 제조 방법 | |
US4153685A (en) | Bismuth complex preparations | |
GB2451713A (en) | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation | |
EP0308362B1 (de) | Eisen-Citrat-Komplex, Verfahren für seine Herstellung und seine pharmazeutische Verwendung | |
KR100556865B1 (ko) | Fe(ⅲ), 폴리히드록실레이트 및 오브알부민으로 구성된 복합체 | |
Terato et al. | Studies on iron absorption: I. The role of low molecular polymer in iron absorption | |
KR100563361B1 (ko) | 페로-숙신일카제인 착화물, 그 제조방법 및 이를 함유하는 약제조성무류 | |
DE69212947T2 (de) | Conalbumin und seine Derivate enthaltende Eisenkomplexe | |
JPS62209100A (ja) | 生体に有用な性質を持つグロビン及びアセチルグロビンの鉄誘導体、その調製法及び薬学的処方物 | |
JPH01146900A (ja) | 鉄含量が高い可溶性ポリペプチド誘導体とその製法及びこれを含有する製薬組成物 | |
DE69431454T2 (de) | Amylase Inhibitoren | |
US4939092A (en) | Proteinaceous derivatives containing iron in highly bioavailable form, preparation thereof and pharmaceutical compositions containing them | |
KR101017432B1 (ko) | 함당산화철 제조방법 | |
FR2534589A1 (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynucleaire de fer iii comme ingredient actif | |
KR100340095B1 (ko) | 철분-트랜스페린 추출물의 제조방법 | |
WO1993008830A1 (en) | Compounds of bioavailable iron with acylated ovotransferrin or with acylated hydrolysis derivatives thereof | |
KR20020033020A (ko) | 3가철의 폴리히드록실화 착체(폴리알코올)를 가진 가용성알부민의 첨가생성물, 그 취득방법, 그 첨가생성물을포함한 의약조성물 및 식이요법 조성물 | |
CN118126122A (zh) | 一种香菇来源的具有钙离子结合能力和促进钙吸收效果的多肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130130 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140214 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150216 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160212 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170210 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180226 Year of fee payment: 13 |
|
EXPY | Expiration of term |